Concepedia

Phase I Study of Chimeric Human/Murine Anti–Ganglioside G<sub>D2</sub>Monoclonal Antibody (ch14.18) With Granulocyte-Macrophage Colony-Stimulating Factor in Children With Neuroblastoma Immediately After Hematopoietic Stem-Cell Transplantation: A Children’s Cancer Group Study

M. Fevzi Özkaynak, Paul M. Sondel, Mark Krailo, Jacek Gan, Brad Javorsky, Ralph A. Reisfeld, Katherine K. Matthay, Gregory H. Reaman, Robert C. Seeger

Journal of Clinical Oncology · 2000 · 186 citations · 28 references

DOI

Abstract

ch14.18 can be administered with GM-CSF after HSCT in patients with neuroblastoma with manageable toxicities. The MTD is 40 mg/m(2)/d for 4 days when given in this schedule with GM-CSF.

References

28

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

Albert F. LoBuglio, Richard Wheeler, J M Trang et al. · Proceedings of the National Academy of Sciences · 1989 · 526 citations · Full text

, , +15

Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients.

Gregor Schulz, David A. Cheresh, Nissi Varki et al. · PubMed · 1984 · 372 citations

, , +18

Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.

Nai‐Kong V. Cheung, Ulla M. Saarinen, John E. Neely et al. · PubMed · 1985 · 323 citations

, , +12

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

Alice L. Yu, M. M. Uttenreuther-Fischer, Chiun‐Sheng Huang et al. · Journal of Clinical Oncology · 1998 · 249 citations

A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

R. Handgretinger, Kelly E. Anderson, Peter Lang et al. · European Journal of Cancer · 1995 · 211 citations

, , +7